Plus Therapeutics, Inc. announced on August 26, 2025, that it received a letter from Nasdaq on August 22, 2025, confirming its compliance with Nasdaq Listing Rule 5550(b). This rule pertains to the Market Value of Listing Securities (MVLS) standard and the alternative stockholders’ equity threshold.
The company now satisfies two alternative criteria under Nasdaq Listing Rule 5550, demonstrating its adherence to key financial and market capitalization requirements. This compliance resolves previous concerns regarding its listing status.
As a result, Nasdaq permitted the company the remainder of the previously announced grace period to regain compliance with the $1.00 bid price rule, extending the deadline through November 12, 2025. The prior September 8, 2025, deadline for the bid price deficiency no longer applies.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.